Meta description: A regulatory update on BaroStim trial for heart failure class three in Northwell Health outlines current recruitment and safety considerations.
Publication date context: 2026-02-11T13:39:54.000Z. A Northwell Health led trial evaluating BaroStim in patients with NYHA Class III heart failure is listed as recruiting. The ClinicalTrials.gov record NCT07399587 shows Northwell Health as sponsor and identifies BaroStim as the investigational device used in this study. The registry notes recruitment status but provides no efficacy or safety results in the source text. Stakeholders should interpret the data as a registry level record intended to document enrollment and device designation rather than as a source of outcome evidence at this stage.
What is the BaroStim trial about?
The registry indicates the target population as adults with heart failure classified as NYHA Class III. BaroStim is identified as the investigational device used in this study. The sponsor listed for the trial is Northwell Health. Recruitment is recorded as ongoing, and the text does not include endpoints or study design specifics. The description reflects a registry entry focused on enrollment and device designation rather than trial outcomes.
Enrollment and device specifics
Enrollment criteria are described in the ClinicalTrials.gov record, with the patient population and device as described above. The document notes the BaroStim device as the investigational component. The registry does not disclose detailed inclusion or exclusion criteria in the provided text.
What are the known trial details and registry data?
The trial is registered under the identifier NCT07399587 and is listed as recruiting. The sponsor is Northwell Health. BaroStim is identified as the investigational device. No outcome data are available in the source text, and the record cautions that results are not yet posted.
External reference: ClinicalTrials.gov entry for NCT07399587 accessible at https://clinicaltrials.gov/study/NCT07399587?term=medical+device.
What regulatory notes apply?
The information derives from a registry entry and should be interpreted as a snapshot of recruitment status and device designation. The text reflects an investigational device study and is intended for regulatory context only. Claims regarding efficacy or final safety conclusions require full trial results and formal regulatory evaluation. Sponsor statements are presented as such when stated in the registry.
Current status and potential care implications
Current status indicates ongoing enrollment. The absence of results in the source text means clinicians should avoid drawing conclusions about effectiveness from this document alone. Future results could influence practice patterns and regulatory considerations for this device.
FAQ
- Q1 What is BaroStim used for in this study?
A1 The source text identifies BaroStim as the investigational device used in this trial for patients with NYHA Class III heart failure. - Q2 Is there reported trial outcome data?
A2 No outcomes are provided in the source text. - Q3 Where can I access the registry entry?
A3 The ClinicalTrials.gov page for NCT07399587 is listed in the source text and the external reference is included. - Q4 When are results expected, if any?
A4 The text does not provide a timeline for results.
Conclusion and next steps
This regulatory update presents the ongoing BaroStim trial in Northwell Health for patients with NYHA Class III heart failure. It confirms recruitment status and device designation while avoiding claims about efficacy. Readers should monitor the registry and official trial postings for updates on enrollment, safety signals and eventual results that could inform regulatory discussions and clinical practice.
Disclaimer
This article is intended for professionals and does not provide legal advice.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07399587?term=medical+device